These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8781574)
1. The clinical use of mutagenic anticancer drugs. Ferguson LR; Pearson AE Mutat Res; 1996 Aug; 355(1-2):1-12. PubMed ID: 8781574 [TBL] [Abstract][Full Text] [Related]
2. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents. Vogel EW; Barbin A; Nivard MJ; Stack HF; Waters MD; Lohman PH Mutat Res; 1998 May; 400(1-2):509-40. PubMed ID: 9685708 [TBL] [Abstract][Full Text] [Related]
3. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Sanderson BJ; Ferguson LR; Denny WA Mutat Res; 1996 Aug; 355(1-2):59-70. PubMed ID: 8781577 [TBL] [Abstract][Full Text] [Related]
4. Comments on the carcinogenic, mutagenic, and teratogenic properties of anticancer drugs. Muggia FM; Ziegler J Recent Results Cancer Res; 1980; 74():306-11. PubMed ID: 7444147 [TBL] [Abstract][Full Text] [Related]
5. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. McGregor D Crit Rev Toxicol; 2007; 37(10):887-914. PubMed ID: 18027166 [TBL] [Abstract][Full Text] [Related]
6. SOS chromotest results in a broader context: empirical relationships between genotoxic potency, mutagenic potency, and carcinogenic potency. White PA; Rasmussen JB Environ Mol Mutagen; 1996; 27(4):270-305. PubMed ID: 8665872 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of fecal mutagenicity and colorectal cancer risk. de Kok TM; van Maanen JM Mutat Res; 2000 Jul; 463(1):53-101. PubMed ID: 10838209 [TBL] [Abstract][Full Text] [Related]
8. Limitations of urinary mutagen assays for monitoring occupational exposure to antineoplastic drugs. Tuffnell PG; Gannon MT; Dong A; DeBoer G; Erlichman C Am J Hosp Pharm; 1986 Feb; 43(2):344-8. PubMed ID: 3513557 [TBL] [Abstract][Full Text] [Related]
9. Occupational exposure to anticancer drug--potential and real hazards. Sorsa M; Hemminki K; Vainio H Mutat Res; 1985 Sep; 154(2):135-49. PubMed ID: 3929080 [TBL] [Abstract][Full Text] [Related]
10. Genotoxicity of 1,3-butadiene and its epoxy intermediates. Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF; Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413 [TBL] [Abstract][Full Text] [Related]
11. Mutagenicity of stereochemical configurations of 1,3-butadiene epoxy metabolites in human cells. Meng RQ; Hackfeld LC; Hedge RP; Wisse LA; Redetzke DL; Walker VE; Res Rep Health Eff Inst; 2010 Jun; (150):1-34; discussion 35-41. PubMed ID: 20853577 [TBL] [Abstract][Full Text] [Related]
12. [Risks of using cytostatic drugs in veterinary medical practice]. Pellicaan CH; Teske E Tijdschr Diergeneeskd; 1999 Apr; 124(7):210-5. PubMed ID: 10214684 [TBL] [Abstract][Full Text] [Related]
13. Investigations on potential co-mutagenic effects of formaldehyde. Speit G; Linsenmeyer R; Duong G; Bausinger J Mutat Res; 2014 Feb; 760():48-56. PubMed ID: 24361396 [TBL] [Abstract][Full Text] [Related]
14. Perspectives on occupational exposure to antineoplastic drugs. Fishbein L Arch Geschwulstforsch; 1987; 57(3):219-48. PubMed ID: 3304187 [TBL] [Abstract][Full Text] [Related]
15. A review of the mutagenicity and rodent carcinogenicity of ambient air. Claxton LD; Woodall GM Mutat Res; 2007; 636(1-3):36-94. PubMed ID: 17451995 [TBL] [Abstract][Full Text] [Related]
16. Non-oncogenic sequelae of cancer chemotherapy. Jaffe N Radiology; 1975 Jan; 114(1):167-73. PubMed ID: 1208857 [TBL] [Abstract][Full Text] [Related]
17. Mutagenicity of anticancer drugs in mammalian germ cells. Witt KL; Bishop JB Mutat Res; 1996 Aug; 355(1-2):209-34. PubMed ID: 8781584 [TBL] [Abstract][Full Text] [Related]
18. Comparative mutagenicity of chemicals selected for test in the International Program on Chemical Safety's collaborative study on plant systems for the detection of environmental mutagens. Grant WF; Salamone MF Mutat Res; 1994 Oct; 310(2):187-209. PubMed ID: 7523891 [TBL] [Abstract][Full Text] [Related]
19. [General problems in the study of the mutagenic properties of drugs]. Durnev AD; Volgareva GM; Seredenin SB Eksp Klin Farmakol; 1998; 61(2):4-12. PubMed ID: 9621164 [TBL] [Abstract][Full Text] [Related]
20. Sister chromatid exchanges induced by cancer chemotherapeutic agents in vitro and in vivo: consideration of the hazard of drugs as possible mutagens and carcinogens causing second malignancies. Abe T; Tsuda S; Maekawa T; Taniwaki M; Sonoda Y; Ide T; Misawa S; Takino T; Inoue K Cancer Treat Rep; 1985 May; 69(5):505-14. PubMed ID: 4005873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]